

**REMARKS**

Claims 13, 14 and 34-36 are all the claims pending in the application.

In the Advisory Action, the Examiner states that the evidence in support of enablement, i.e., the cited URL, of claims 13 and 14 requires further consideration. The Examiner also states that if Applicants rely on the teachings of the document, Applicants should cite the URL in an IDS. Finally, the Examiner requests that Applicants identify the specific references available via the URL that Applicants are relying on.

Applicants disagree that the URL needs to be cited in an IDS. The URL is being cited as evidence of patentability. Thus, according to the MPEP section 609.05(c), the evidence must be considered by the Examiner without it being cited in an IDS.

The reference available via the URL that Applicants rely upon is Brahmer, J.R. et al., "Safety and activity of MDX-1106 (ONO-4538), and anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies," J. Clin. Oncol. 26:2008 (May 20 suppl; abstr 3006).

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


Respectfully submitted,

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

**65565**

CUSTOMER NUMBER

  
Susan J. Mack  
Registration No. 30,951

Date: August 26, 2008